18/06/2025
TruSight Oncology 500 ctDNA v2 – Comprehensive Liquid Biopsy for Pan-Cancer Profiling
We are excited to present Illumina's TruSight Oncology 500 ctDNA v2, a cutting-edge NGS solution for comprehensive, non-invasive cancer profiling using circulating tumor DNA (ctDNA) from plasma.
________________________________________
Key Highlights:
• Minimal Sample Required – Only 20 ng of cfDNA (~4 mL of plasma) is needed, making it ideal for liquid biopsy when tissue is limited or inaccessible.
• Ultra-Deep Sequencing – Achieves >35,000× mean coverage per sample using NovaSeq systems, enabling detection of variants as low as 0.2% VAF with exceptional sensitivity and specificity.
• Broad Variant Detection – Detects SNVs, indels, CNVs, and gene fusions including ALK, ROS1, NTRK, and RET.
• Immuno-Oncology Insights – Includes reliable MSI detection (down to 0.3% tumor fraction) and blood-based TMB (bTMB) analysis with high concordance (R² = 0.992).
• Advanced Bioinformatics – Powered by DRAGEN for fast and accurate variant calling, error correction, and integrated TMB/MSI scoring.
• Automation-Compatible – Supports manual or automated workflows with liquid-handling robots (e.g. Hamilton), reducing hands-on time by 40% and enabling high-throughput efficiency.
• Fast Turnaround Time – Results in as little as 4 days from cfDNA extraction to report.
________________________________________
Why Choose TSO 500 ctDNA v2?
✔️ Non-invasive and patient-friendly
✔️ Pan-cancer coverage across 523 genes
✔️ High sensitivity and precision for low-frequency variants
✔️ Automation-ready and scalable workflow
📩 For more information, workflow details, or technical consultation, feel free to contact us.